<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2	DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                            750 mg taken 3 times a day (7-9 hours apart) with food (not low fat). (2, 12.3, 17.4)<BR>                            INCIVEK must be administered with both peginterferon alfa and ribavirin for all patients for 12 weeks, followed by a response-guided regimen of either 12 or 36 additional weeks of peginterferon alfa and ribavirin depending on viral response and prior response status. (2)<BR>                            For specific dosage instructions for peginterferon alfa and ribavirin, refer to their respective prescribing information. (2)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1	INCIVEK/Peginterferon Alfa/Ribavirin Combination Treatment<BR>                     <BR>                        The recommended dose of INCIVEK tablets is 750 mg (two 375-mg tablets) taken orally 3 times a day (7-9 hours apart) with food (not low fat) [see <BR>                              Clinical Pharmacology (12.3)<BR>                            and <BR>                              Patient Counseling Information (17.4)<BR>                           ].<BR>                        For specific dosage instructions for peginterferon alfa and ribavirin, refer to their respective prescribing information.<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Duration of Treatment <BR>                              <BR>                              The recommended duration of treatment with INCIVEK is 12 weeks in combination with peginterferon alfa and ribavirin. HCV RNA levels should be monitored at weeks 4 and 12 to determine combination treatment duration and assess for treatment futility (Tables 1 and 2).<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%" ID="table1"><BR>                                 <caption>Table 1: Recommended Treatment Duration (See also<linkHtml href="#table2"> Table 2 </linkHtml>for Treatment Futility Rules)</caption><BR>                                 <col width="25%" align="left" valign="top"/><BR>                                 <col width="30%" align="left" valign="top"/><BR>                                 <col width="30%" align="left" valign="top"/><BR>                                 <col width="15%" align="left" valign="top"/><BR>                                 <tbody><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" colspan="4"><BR>                                          <content styleCode="bold">Treatment-Na&#239;ve and Prior Relapse Patients</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td styleCode="Lrule Botrule" rowspan="2" valign="bottom" align="center"><BR>                                          <content styleCode="bold">HCV RNA<footnote ID="table1a">In clinical trials, HCV RNA in plasma was measured using a COBAS<sup>&#174;</sup> TaqMan<sup>&#174;</sup> assay with a lower limit of quantification of 25 IU/mL and a limit of detection of 10 IU/mL. See <content styleCode="italics"><BR>                                                   <linkHtml href="#S5.5">Laboratory Tests (5.5)</linkHtml><BR>                                                </content> for a description of HCV RNA assay recommendations.</footnote><BR>                                          </content><BR>                                       </td><BR>                                       <td styleCode="Lrule"><BR>                                          <content styleCode="bold">Triple Therapy</content><BR>                                       </td><BR>                                       <td styleCode="Lrule"><BR>                                          <content styleCode="bold">Dual Therapy</content><BR>                                       </td><BR>                                       <td styleCode="Lrule Rrule Botrule" rowspan="2"><BR>                                          <content styleCode="bold">Total Treatment Duration</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule">INCIVEK,<br/>peginterferon alfa and ribavirin</td><BR>                                       <td styleCode="Lrule" valign="bottom">peginterferon alfa and ribavirin</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" align="center">Undetectable (Target Not Detected) at Weeks 4 and 12</td><BR>                                       <td styleCode="Rrule">First 12 weeks</td><BR>                                       <td styleCode="Rrule">Additional 12 weeks</td><BR>                                       <td styleCode="Rrule">24 weeks</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" align="center">Detectable (1000 IU/mL or less) at Weeks 4 and/or 12</td><BR>                                       <td styleCode="Rrule">First 12 weeks</td><BR>                                       <td styleCode="Rrule">Additional 36 weeks</td><BR>                                       <td styleCode="Rrule">48 weeks</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" colspan="4"><BR>                                          <content styleCode="bold">Prior Partial and Null Responder Patients</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td styleCode="Botrule Lrule Rrule" rowspan="2"/><BR>                                       <td styleCode="Rrule"><BR>                                          <content styleCode="bold">Triple Therapy</content><BR>                                       </td><BR>                                       <td styleCode="Rrule"><BR>                                          <content styleCode="bold">Dual Therapy</content><BR>                                       </td><BR>                                       <td styleCode="Botrule Rrule" rowspan="2"><BR>                                          <content styleCode="bold">Total Treatment Duration</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">INCIVEK,<br/>peginterferon alfa and ribavirin</td><BR>                                       <td styleCode="Rrule" valign="bottom">peginterferon alfa and ribavirin</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td styleCode="Lrule Rrule">All Patients</td><BR>                                       <td styleCode="Rrule">First 12 weeks</td><BR>                                       <td styleCode="Rrule">Additional 36 weeks</td><BR>                                       <td styleCode="Rrule">48 weeks</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                              <BR><BR><BR>For the purpose of assessing response-guided therapy eligibility at weeks 4 and 12 (see Table 1), an "undetectable" HCV RNA (Target Not Detected) result is required; a confirmed "detectable but below limit of quantification" HCV RNA result should not be considered equivalent to an "undetectable" HCV RNA (Target Not Detected) result [see <BR>                                    Laboratory Tests (5.5)<BR>                                 ].<BR>                              Treatment-na√Øve patients with cirrhosis who have undetectable HCV RNA (Target Not Detected) at weeks 4 and 12 of INCIVEK combination treatment may benefit from an additional 36 weeks of peginterferon alfa and ribavirin (48 weeks total) [see <BR>                                    Clinical Studies (14.2)<BR>                                 ].<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2	Dose Reduction<BR>                     <BR>                        To prevent treatment failure, the dose of INCIVEK must not be reduced or interrupted. Refer to the respective prescribing information for dose modification of peginterferon alfa and ribavirin [see <BR>                              Warnings and Precautions (5.6)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.3	Discontinuation of Dosing<BR>                     <BR>                        Patients with inadequate viral response are unlikely to achieve SVR, and may develop treatment-emergent resistance substitutions [see <BR>                              Microbiology (12.4)<BR>                           ]. Discontinuation of therapy is recommended in all patients with (1) HCV RNA levels of greater than 1000 IU/mL at Treatment Week 4 or 12; or (2) confirmed detectable HCV RNA levels at Treatment Week 24 (see Table 2).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%" ID="table2"><BR>                           <caption>Table 2: Treatment Futility Rules: All Patients</caption><BR>                           <col width="40%" align="left" valign="top"/><BR>                           <col width="60%" align="left" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">HCV RNA</th><BR>                                 <th styleCode="Rrule">Action</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Week 4 or Week 12: Greater than 1000 IU/mL</td><BR>                                 <td styleCode="Rrule">Discontinue INCIVEK and peginterferon alfa and ribavirin (INCIVEK treatment complete at 12 weeks)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Week 24: Detectable</td><BR>                                 <td styleCode="Rrule">Discontinue peginterferon alfa and ribavirin</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>If peginterferon alfa or ribavirin is discontinued for any reason, INCIVEK must also be discontinued.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>